Additionally, the use of antibody blockade targeting TLR2, TLR4, or C5aR showed considerable inhibitory effects on the bacteria-induced release of pro-fibrotic and pro-inflammatory mediators by peritoneal leukocytes in cases of infection-related peritoneal fibrosis. The gene discussed is TLR2; the disease is Peritoneal Fibrosis.